Company Profile: Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte is developing a treatment for ovarian cancer, which is currently entering Phase III trials.Return Since IPO: 135% IPO Date: Feb. 4 Offer Price: Endocyte offered 12.5 million shares at $6 per share Analyst Consensus: Of the four firms following Endocyte, including RBC Capital and Leerink Swan, all rate Endocyte "buy." -- Written by Robert Holmes in Boston.
>To contact the writer of this article, click here: Robert Holmes. >To follow Robert Holmes on Twitter, go to http://twitter.com/RobTheStreet. >To submit a news tip, send an email to: firstname.lastname@example.org.